---
figid: PMC8558801__10.1177_20420188211054692-fig1
figtitle: 'Evolution of anaplastic thyroid cancer management: perspectives in the
  era of precision oncology'
organisms:
- Homo sapiens
- Mus musculus
organisms_ner:
- Mus musculus
- Homo sapiens
- Drosophila melanogaster
pmcid: PMC8558801
filename: 10.1177_20420188211054692-fig1.jpg
figlink: /pmc/articles/PMC8558801/figure/fig1-20420188211054692/
number: F1
caption: Schematic review of cellular pathways targeted by oral antineoplastic agents
  in thyroid cancer.Tyrosine kinase receptors including vascular endothelial growth
  factor receptor (VEGFR), fibroblast growth factor receptor (FGFR), platelet-derived
  growth factor α (PDGFα), and RET can activate internal MAPK pathways which can lead
  to tumor proliferation; in a similar way, TRK and RET fusions can lead to tumorigenesis.
  The figure above highlights several multikinase inhibitors described in this article
  with their respective target receptors or fusions. In addition, dabrafenib and trametinib
  inhibit BRAF and MEK, respectively, from the MAPK pathway which has led to improvement
  in survival on BRAF-altered ATC cases.
papertitle: 'Evolution of anaplastic thyroid cancer management: perspectives in the
  era of precision oncology.'
reftext: Sarimar Agosto Salgado. Ther Adv Endocrinol Metab. 2021;12:20420188211054692.
year: '2021'
doi: 10.1177/20420188211054692
journal_title: Therapeutic Advances in Endocrinology and Metabolism
journal_nlm_ta: Ther Adv Endocrinol Metab
publisher_name: SAGE Publications
keywords: anaplastic thyroid cancer | dabrafenib | precision oncology | trametinib
  | tyrosine kinase inhibitors
automl_pathway: 0.9599266
figid_alias: PMC8558801__F1
figtype: Figure
redirect_from: /figures/PMC8558801__F1
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC8558801__10.1177_20420188211054692-fig1.html
  '@type': Dataset
  description: Schematic review of cellular pathways targeted by oral antineoplastic
    agents in thyroid cancer.Tyrosine kinase receptors including vascular endothelial
    growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR), platelet-derived
    growth factor α (PDGFα), and RET can activate internal MAPK pathways which can
    lead to tumor proliferation; in a similar way, TRK and RET fusions can lead to
    tumorigenesis. The figure above highlights several multikinase inhibitors described
    in this article with their respective target receptors or fusions. In addition,
    dabrafenib and trametinib inhibit BRAF and MEK, respectively, from the MAPK pathway
    which has led to improvement in survival on BRAF-altered ATC cases.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Ntrk1
  - Ptch1
  - Ret
  - Pik3r1
  - Akt1
  - Mtor
  - ras
  - Hras
  - Kras
  - Rem1
  - Braf
  - Braf-rs1
  - Mdk
  - Ephb2
  - Mapk1
  - KDR
  - FLT1
  - FLT4
  - NTRK1
  - TPM3
  - F9
  - TAS2R38
  - PTCH1
  - RET
  - CCDC6
  - PIK3CA
  - PIK3CB
  - PIK3CD
  - PIK3CG
  - PIK3R3
  - PIK3R4
  - PIK3R5
  - PIK3R6
  - PIK3R1
  - PIK3R2
  - AKT1
  - AKT2
  - AKT3
  - MTOR
  - FGFR1
  - FGFR2
  - FGFR3
  - FGFR4
  - FGFRL1
  - KRAS
  - HRAS
  - NRAS
  - BRAF
  - MAP2K7
  - MAP2K1
  - MAP2K2
  - EPHB2
  - MAPK1
  - MAPK3
  - PDGFA
  - PDGFB
  - PDGFC
  - PDGFD
  - Pvr
  - trk
  - ptc
  - reticulated
  - reti
  - rets
  - Pi3K21B
  - Pi3K59F
  - Pi3K68D
  - Pi3K92E
  - Akt
  - Tor
  - btl
  - htl
  - Ras64B
  - Ras85D
  - Dsor1
  - Mtk
  - Erk7
  - rl
---
